Format

Send to

Choose Destination
Gynecol Endocrinol. 2013 Feb;29(2):98-100. doi: 10.3109/09513590.2012.730578. Epub 2012 Oct 30.

Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.

Author information

1
Second Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital, Athens, Greece. kalamp@yahoo.com

Abstract

One of the most serious complications of assisted reproduction techniques is ovarian hyperstimulation syndrome (OHSS). OHSS not only increases morbidity and mortality in IFV cycles, but also causes significant other problems, as cancelled in vitro fertilization (IVF) cycles, prolonged hospitalization, causing emotional and sociofinancial consequences. Several treatments for OHSS have been proposed and among these Cabergoline (Cb2). Despite the above-mentioned beneficial effect, Cb2 has not been widely used in everyday's clinical practice. With our study, we try to review all studies with strong evidence examining Cb2 use for OHSS prevention.

PMID:
23110560
DOI:
10.3109/09513590.2012.730578
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center